publication date: Jan. 20, 2017

Guest Editorial NCI formulary, moonshot and public-private partnerships

By Howard Fingert

Senior medical director in oncology clinical research

Takeda Pharmaceuticals Inc.

FingertHoward

 

Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.

Certainly, the NCI Formulary does offer new opportunities for speed and innovation; however, the resulting research programs will also introduce new challenges that will likely be far from easy, coupled with important opportunities for creative engagement and support from industry collaborators.

Like other investigator-initiated trials, researchers from NCI Cancer Centers will investigate Formulary drugs to develop new knowledge about single agents or combination regimens, and the results will likely add to cancer sciences through publication.

However, the overall goals of the National Cancer Moonshot Initiative do not begin and end with a journal publication; instead, primary goals include introduction of important new therapies that will be broadly accessible and provide clinical utility and/or cures.

Building on recent promising, but largely partial, successes with immune-oncology … Continue reading NCI formulary, moonshot and public-private partnerships

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.